The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority?
CVD is the primary cause of morbidity and mortality in patients who have diabetes mellitus. Most such patients have at least one lipid abnormality. Managing these complex lipid disorders is a crucial component of comprehensive diabetes mellitus care and limits the risk for cardiovascular morbidity and mortality. With the high prevalence of mixed lipid disorders, management must focus on all components of the lipid profile. Lowering LDL-C levels remains the first priority, but abnormalities in HDL-C and TG levels also should be treated aggressively. Statins, fibrates, and niacin, along with newer therapies such as ezetimibe, can improve significantly components of the lipid profile. Alone or in combination, these agents can treat the dyslipidemia of diabetes mellitus effectively and safely.
Kendall
David M
DM
International Diabetes Center, 3800 Park Nicollet Boulevard, Minneapolis, MN 55416-2699, USA. kendad@parknicollet.com
D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000097:blood* / Q000473:pathology / Q000628:therapy; D008076:Cholesterol, HDL / Q000097:blood*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000473:pathology / Q000628:therapy; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000473:pathology / Q000628:therapy; D007333:Insulin Resistance / Q000502:physiology; D014280:Triglycerides / Q000097:blood*
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D014280:Triglycerides